Strategy and current situation analysis for dose selection of novel anti-cancer drugs in ChinaZHU Zhong-ling, YU Jun2417-2425
Patent-based topic mining and technology evolution analysis in the field of messenger ribonucleic acid delivery systemsZHANG Min, WU Tong, WEI Dong-lin, ZHANG Qing, ZHAO Ying-ying, YUAN Hong-mei2426-2432
Analysis of the medication patterns and characteristics of traditional Chinese medicine in the treatment of high-risk pulmonary nodulesZENG Yin, ZHANG Gan-lin, ZHANG Xing-han, ZHANG Huai-rui, YANG Guo-wang2433-2437
Establishing patient-centric specifications for therapeutic biological productsLI Yi-jun, WEI Kai-kun2438-2445
General considerations and case analysis of non-clinical studies of oligonucleotide therapeuticsFENG Zheng, YUE Yan, LI De-li, LIU Qi-yao, FAN A-li, HUANG Fang-hua, GONG Xin-jiang2446-2455
Impurities analysis and control strategies of gadobutrol contrast agentsDONG Chen-huan, WANG Gang, HE Yan2456-2461
The historical evolution and perspective of the regulation on cell and gene therapy products in ChinaJIANG Lu-yi, KANG Qi, JIN Chun-lin2462-2466
Research on innovative regulatory pathways for cell and gene therapy productsYANG Li, HUANG Ge-yun, ZHANG Jie, WANG He-huan2467-2475
Research advances on lysosomal storage diseases and the therapeutic replacement enzymesYANG Ke-qin, CAO Yun-song, MA Lan, YANG Yan, WANG Wei2476-2481
Research progress of enzyme-responsive peptide self-assembly for tumor imagingWU Yu-jing, ZHOU Peng, WU Hao, XIE Min-hao2482-2488